Actively Recruiting
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
Led by Institut Curie · Updated on 2025-09-08
50
Participants Needed
3
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
CONDITIONS
Official Title
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with suspicion of localised thymic epithelial tumour.
- Age ≥ 18 years.
- Treatment-naïve patient for this disease.
- Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
- Signed informed consent form of the patient.
You will not qualify if you...
- Neoadjuvant chemotherapy.
- No social security affiliation.
- Person under legal protection.
- Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Institut Curie Paris
Paris, France
Actively Recruiting
2
Institut Mutualiste Montsouris
Paris, France
Actively Recruiting
3
Hôpital FOCH
Suresnes, France
Actively Recruiting
Research Team
C
Clémence BASSE, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here